Crispr Therapeutics AG (NASDAQ:CRSP) Director Thomas Woiwode sold 1,700 shares of Crispr Therapeutics stock in a transaction on Friday, November 24th. The stock was sold at an average price of $20.21, for a total value of $34,357.00. Following the sale, the director now owns 8,218 shares in the company, valued at $166,085.78. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Thomas Woiwode also recently made the following trade(s):

  • On Monday, November 27th, Thomas Woiwode sold 200 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.24, for a total value of $4,048.00.

Crispr Therapeutics AG (NASDAQ CRSP) traded up $0.34 during mid-day trading on Thursday, reaching $19.00. The company’s stock had a trading volume of 223,845 shares, compared to its average volume of 139,860. Crispr Therapeutics AG has a 1-year low of $11.63 and a 1-year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.77) EPS. equities research analysts expect that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Granahan Investment Management Inc. MA grew its holdings in Crispr Therapeutics by 51.7% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after buying an additional 89,839 shares in the last quarter. Allianz Asset Management GmbH purchased a new position in Crispr Therapeutics during the 3rd quarter valued at about $2,384,000. Adams Street Partners LLC purchased a new position in Crispr Therapeutics during the 3rd quarter valued at about $1,019,000. Tiff Advisory Services Inc. purchased a new position in Crispr Therapeutics during the 3rd quarter valued at about $505,000. Finally, Wells Fargo & Company MN grew its holdings in Crispr Therapeutics by 129.8% during the 3rd quarter. Wells Fargo & Company MN now owns 18,352 shares of the company’s stock valued at $328,000 after buying an additional 10,365 shares in the last quarter. 24.55% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently weighed in on the company. Barclays reissued a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a report on Friday, September 8th. SunTrust Banks reissued a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a report on Friday, November 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Finally, Chardan Capital reissued a “buy” rating on shares of Crispr Therapeutics in a report on Monday, August 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $22.38.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/30/thomas-woiwode-sells-1700-shares-of-crispr-therapeutics-ag-crsp-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.